Aquestive Therapeutics Files Definitive Proxy, Reveals Widening Losses and Executive Compensation Details
AQST sits 92% above its 52-week low of $2.12 on light trading volume (0.4× avg).
Summary
Aquestive Therapeutics filed its definitive proxy statement, revealing a substantial increase in net losses to $83.78 million in 2025 and executive compensation details, including high "Compensation Actually Paid" for the CEO despite financial deterioration.
Key Events · Corporate Governance and Compliance · AQST
-
Annual Meeting Proposals
Shareholders will vote on the election of three Class II directors, an advisory resolution on executive compensation, and the ratification of KPMG LLP as the independent auditor at the virtual annual meeting on June 10, 2026.
-
Significant Increase in Net Loss
The company reported a net loss of $(83.78) million for 2025, a substantial increase from $(44.14) million in 2024 and $(7.87) million in 2023, indicating a worsening financial trend.
-
Executive Compensation Details
The Principal Executive Officer's "Compensation Actually Paid" for 2025 was $11.03 million. Performance stock units (PSUs) have stock price vesting thresholds ($6.00, $7.00, $8.00) that are significantly above the current stock price of $4.06, making these awards currently underwater.
-
Executive Departure and Severance
Lori J. Braender ceased serving as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026, but continues as Corporate Secretary. She is entitled to a severance package including a pro-rata bonus, 12 months of monthly payments, continued insurance, and full vesting of unvested equity awards at target.
Analysis · AQST · Life Sciences
This definitive proxy statement (DEF 14A) outlines the agenda for the upcoming annual meeting, including routine proposals for director elections and advisory votes on executive compensation and auditor ratification. Critically, the filing's "Pay Versus Performance Disclosure" highlights a significant increase in net losses, from $(7.87) million in 2023 to $(83.78) million in 2025, indicating a worsening financial trend. Despite this, the Principal Executive Officer's "Compensation Actually Paid" for 2025 was substantial at $11.03 million, raising questions about pay-for-performance alignment. Furthermore, the vesting conditions for performance stock units (PSUs) are tied to stock price goals ($6.00 threshold, $7.00 target, $8.00 maximum), which are currently well above the company's stock price of $4.06, suggesting that a significant portion of executive equity incentives are currently underwater. The company also disclosed the transition of its Chief Legal Officer and Chief Compliance Officer, Lori J. Braender, with a severance package that includes full vesting of equity awards at target, and noted several delinquent Section 16(a) reports for multiple executives due to administrative oversight.
At the time of this filing, AQST was trading at $4.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $497.9M. The 52-week trading range was $2.12 to $7.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.